Table 3.
Adverse events and reasons for treatment discontinuation
| Adverse events | PPI users, n = 43 (43.4%) | PPI nonusers, n = 56 (56.6%) | p value | ||
|---|---|---|---|---|---|
| Grade 1–2, n (%) | Grade 3–4, n (%) | Grade 1–2, n (%) | Grade 3–4, n (%) | ||
| Diarrhea | 27 (64.3) | 1 (2.4) | 33 (58.9) | 0 (0) | .401 |
| Nausea | 15 (34.9) | 0 (0) | 26 (46.4) | 2 (3.4) | |
| Loss of appetite | 19 (45.2) | 0 (0) | 15 (27.3) | 2 (3.6) | .106 |
| Dyspepsia | 10 (23.8) | 0 (0) | 11 (2.0) | 0 (0) | .652 |
| Mucositis | 15 (35.7) | 1 (2.4) | 21 (38.2) | 0 (0) | .510 |
| Vomiting | 11 (26.2) | 0 (0) | 8 (14.5) | 3 (5.5) | .131 |
| Increased liver function tests | 19 (46.3) | 0 (0) | 25 (45.5) | 0 (0) | .931 |
| Hyponatremia | 11 (26.8) | 0 (0) | 17 (3.9) | 0 (0) | .664 |
| Weight loss a | 21 (53.8) | 4 (10.2) | 24 (47) | 5 (9.8) | .488 |
| Cabozantinib dose reduction | 36 (83.7) | 36 (83.7) | 36 (64.3) | 36 (64.3) | .031 |
| Reasons for treatment discontinuation | .587 | ||||
| Progression | 20 (46.5) | 20 (46.5) | 31 (55.4) | 31 (55.4) | |
| Adverse events | 11 (25.6) | 11 (25.6) | 10 (17.9) | 10 (17.9) | |
a
Data at every visit unavailable for 9 patients: 5 PPI users and 4 PPI nonusers
Abbreviation: PPI, proton pump inhibitor.